The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway

Virus Research

Volumn 195, Issue , 2015, Pages 25-34

  Zhou, Dawei ^a   Wang, Yan ^a   Tokunaga, Kenzo ^b   Huang, Fang ^a   Sun, Binlian ^a   Yang, Rongge ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

APOBEC3G (A3G); Degradation; Encapsidation; HIV 1; Vpr; VprBP

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; PROTEASOME; VPR PROTEIN; APOBEC3G PROTEIN, HUMAN; CARRIER PROTEIN; CYTIDINE DEAMINASE; PROTEIN BINDING; VPR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VPRBP PROTEIN, HUMAN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG DEGRADATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN INTERACTION; VIRION; VIRUS CAPSID; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; BIOLOGY; IMMUNOLOGY; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; PROTEIN DEGRADATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CARRIER PROTEINS; COMPUTATIONAL BIOLOGY; CYTIDINE DEAMINASE; HIV-1; IMMUNOPRECIPITATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84919389946     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.08.021     Document Type: Article

References (60)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59(2):284-291.
2. Ahn J., Vu T., Novince Z., Guerrero-Santoro J., Rapic-Otrin V., Gronenborn A.M. HIV-1 Vpr loads uracil DNA glycosylase-2 onto DCAF1, a substrate recognition subunit of a cullin 4A-ring E3 ubiquitin ligase for proteasome-dependent degradation. J. Biol. Chem. 2010, 285(48):37333-37341.
3. Biard-Piechaczyk M., Borel S., Espert L., de Bettignies G., Coux O. HIV-1, ubiquitin and ubiquitin-like proteins: the dialectic interactions of a virus with a sophisticated network of post-translational modifications. Biol. Cell 2012, 104(3):165-187.
4. Binette J., Dube M., Mercier J., Halawani D., Latterich M., Cohen E.A. Requirements for the selective degradation of CD4 receptor molecules by the human immunodeficiency virus type I Vpu protein in the endoplasmic reticulum. Retrovirology 2007, 4:75.
5. Bishop K.N., Verma M., Kim E.Y., Wolinsky S.M., Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008, 4(12):e1000231.
6. Chen C., Qiu H., Gong J., Liu Q., Xiao H., Chen X.W., Sun B.L., Yang R.G. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Arch. Virol. 2012, 157(7):1301-1312.
7. Chen K., Huang J., Zhang C., Huang S., Nunnari G., Wang F.X., Tong X., Gao L., Nikisher K., Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4T cells. J. Virol. 2006, 80(15):7645-7657.
8. Chen R.X., Le Rouzic E., Kearney J.A., Mansky L.M., Benichou S. Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J. Biol. Chem. 2004, 279(27):28419-28425.
9. Chiu Y.L., Greene W.C. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 2008, 26:317-353.
10. Chiu Y.L., Soros V.B., Kreisberg J.F., Stopak K., Yonemoto W., Greene W.C. Cellular APOBEC3G restricts HIV-1 infection in resting CD4(+) T cells (Retracted Article. See vol. 466, pg 276, 2010). Nature 2005, 435(7038):108-114.
11. DeHart J.L., Planelles V. Human immunodeficiency virus type 1 vpr links proteasomal degradation and checkpoint activation. J. Virol. 2008, 82(3):1066-1072.
12. Esnault C., Heidmann O., Delebecque F., Dewannieux M., Ribet D., Hance A.J., Heidmann T., Schwartz O. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005, 433(7024):430-433.
13. Feng Y.Q., Love R.P., Chelico L. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G. J. Biol. Chem. 2013, 288(9):6083-6094.
14. Goila-Gaur R., Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008, 5:51.
15. Guenzel C.A., Herate C., Le Rouzic E., Maidou-Peindara P., Sadler H.A., Rouyez M.C., Mansky L.M., Benichou S. Recruitment of the nuclear form of uracil DNA glycosylase into virus particles participates in the full infectivity of HIV-1. J. Virol. 2012, 86(5):2533-2544.
16. Hoch J., Lang S.M., Weeger M., Stahlhennig C., Coulibaly C., Dittmer U., Hunsmann G., Fuchs D., Muller J., Sopper S., Fleckenstein B., Uberla K.T. Vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus-monkeys. J. Virol. 1995, 69(8):4807-4813.
17. Iwabu Y., Kinomoto M., Tatsumi M., Fujita H., Shimura M., Tanaka Y., Ishizaka Y., Nolan D., Mallal S., Sata T., Tokunaga K. Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes. J. Biol. Chem. 2010, 285(46):35350-35358.
18. Iwatani Y., Chan D.S.B., Liu L., Yoshii H., Shibata J., Yamamoto N., Levin J.G., Gronenborn A.M., Sugiura W. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(46):19539-19544.
19. Jones K.L., Roche M., Gantier M.P., Begum N.A., Honjo T., Caradonna S., Williams B.R.G., Mak J. X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells. J. Biol. Chem. 2010, 285(24):18603-18614.
20. Kaiser S.M., Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 2006, 80(2):875-882.
21. Kinomoto M., Kanno T., Shimura M., Ishizaka Y., Kojima A., Kurata T., Sata T., Tokunaga K. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res. 2007, 35(9):2955-2964.
22. Klockow L.C., Sharifi H.J., Wen X.Y., Flagg M., Furuya A.K.M., Nekorchuk M., de Noronha C.M.C. The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. Virology 2013, 444(1-2):191-202.
23. Kogan M., Rappaport J. HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology 2011, 8:25.
24. Koyama T., Sun B.L., Tokunaga K., Tatsumi M., Ishizaka Y. DNA damage enhances integration of HIV-1 into macrophages by overcoming integrase inhibition. Retrovirology 2013, 10:21.
25. Kreisberg J.F., Yonemoto W., Greene W.C. Endogenous factors enhance HIV infection of tissue naive CD4T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 2006, 203(4):865-870.
26. Lang S.M., Weeger M., Stahlhennig C., Coulibaly C., Hunsmann G., Muller J., Mullerhermelink H., Fuchs D., Wachter H., Daniel M.M., Desrosiers R.C., Fleckenstein B. Importance of Vpr for infection of rhesus-monkeys with simian immunodeficiency virus. J. Virol. 1993, 67(2):902-912.
27. Langlois M.A., Neuberger M.S. Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J. Virol. 2008, 82(9):4660-4664.
28. Le Rouzic E., Belaidouni N., Estrabaud E., Morel M., Rain J.C., Transy C., Margottin-Goguet F. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. Cell Cycle 2007, 6(2):182-188.
29. Le Rouzic E., Benichou S. The Vpr protein from HIV-1: distinct roles along the viral life cycle. Retrovirology 2005, 2:11.
30. Magadan J.G., Perez-Victoria F.J., Sougrat R., Ye Y.H., Strebel K., Bonifacino J.S. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLoS Pathog. 2010, 6(4):e1000869.
31. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114(1):21-31.
32. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 2003, 9(11):1398-1403.
33. Mashiach E., Nussinov R., Wolfson H.J. Fiber Dock: flexible induced-fit backbone refinement in molecular docking. Proteins 2010, 78(6):1503-1519.
34. Maudet C., Sourisce A., Dragin L., Lahouassa H., Rain J.C., Bouaziz S., Ramirez B.C., Margottin-Goguet F. HIV-1 Vpr induces the degradation of ZIP and sZIP, adaptors of the NuRD chromatin remodeling complex, by hijacking DCAF1/VprBP. PLoS One 2013, 8(10):e77320.
35. Muckenfuss H., Hamdorf M., Held U., Perkovic M., Lower J., Cichutek K., Flory E., Schumann G.G., Munk C. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 2006, 281(31):22161-22172.
36. Nakagawa T., Mondal K., Swanson P.C. VprBP (DCAF1): a promiscuous substrate recognition subunit that incorporates into both RING-family CRL4 and HECT-family EDD/UBR5 E3 ubiquitin ligases. BMC Mol. Biol. 2013, 14:22.
37. Newman E.N.C., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15(2):166-170.
38. Norman J.M., Mashiba M., McNamara L.A., Onafuwa-Nuga A., Chiari-Fort E., Shen W.W., Collins K.L. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat. Immunol. 2011, 12(10):975-983.
39. Okumura A., Alce T., Lubyova B., Ezelle H., Strebel K., Pitha P.M. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2008, 373(1):85-97.
40. Priet S., Gros N., Navarro J.M., Boretto J., Canard B., Querat G., Sire J. HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Mol. Cell 2005, 17(4):479-490.
41. Romani B., Cohen E.A. Lentivirus Vpr and Vpx accessory proteins usurp the cullin4-DDB1 (DCAF1) E3 ubiquitin ligase. Curr. Opin. Virol. 2012, 2(6):755-763.
42. Rosenstiel P.E., Chan J., Snyder A., Planelles V., D'Agati V.D., Klotman P.E., Klotman M.E. HIV-1 Vpr activates the DNA damage response in renal tubule epithelial cells. AIDS 2009, 23(15):2054-2056.
43. Schrofelbauer B., Hakata Y., Landau N.R. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(10):4130-4135.
44. Schrofelbauer B., Yu Q., Zeitlin S.G., Landau N.R. Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 2005, 79(17):10978-10987.
45. Shatsky M., Nussinov R., Wolfson H.J. A method for simultaneous alignment of multiple protein structures. Proteins 2004, 56(1):143-156.
46. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(6898):646-650.
47. Tokunaga K., Greenberg M.L., Morse M.A., Cumming R.I., Lyerly H.K., Cullen B.R. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J. Virol. 2001, 75(15):6776-6785.
48. Tristem M., Marshall C., Karpas A., Hill F. Evolution of the primate lentiviruses - evidence from Vpx and Vpr. EMBO J. 1992, 11(9):3405-3412.
49. Tuncbag N., Gursoy A., Nussinov R., Keskin O. Predicting protein-protein interactions on a proteome scale by matching evolutionary and structural similarities at interfaces using PRISM. Nat. Protoc. 2011, 6(9):1341-1354.
50. Tuncbag N., Kar G., Gursoy A., Keskin O., Nussinov R. Towards inferring time dimensionality in protein-protein interaction networks by integrating structures: the p53 example. Mol. Biosyst. 2009, 5(12):1770-1778.
51. Wang X., Singh S., Jung H.Y., Yang G.J., Jun S., Sastry K.J., Park J.I. HIV-1 Vpr protein inhibits telomerase activity via the EDD-DDB1-VPRBP E3 ligase complex. J. Biol. Chem. 2013, 288(22):15474-15480.
52. Ward J., Davis Z., DeHart J., Zimmerman E., Bosque A., Brunetta E., Mavilio D., Planelles V., Barker E. HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog. 2009, 5(10):e1000613.
53. Weil A.F., Ghosh D., Zhou Y., Seiple L., McMahon M.A., Spivak A.M., Siliciano R.F., Stivers J.T. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc. Natl. Acad. Sci. U.S.A. 2013, 110(6):E448-E457.
54. Wen X.Y., Klockow L.C., Nekorchuk M., Sharifi H.J., de Noronha C.M.C. The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover. PLoS One 2012, 7(1):e30939.
55. Xu H.Z., Chertova E., Chen J.B., Ott D.E., Roser J.D., Hu W.S., Pathak V.K. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 2007, 360(2):247-256.
56. Yan N., O'Day E., Wheeler L.A., Engelman A., Lieberman J. HIV DNA is heavily uracilated, which protects it from autointegration. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(22):9244-9249.
57. Yang B., Chen K.Y., Zhang C., Huang S., Zhang H. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 2007, 282(16):11667-11675.
58. Yu X.H., Yu Y.K., Liu B.D., Luo K., Kong W., Mao P.Y., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302(5647):1056-1060.
59. Zhao R.Y., Li G., Bukrinsky M.I. Vpr-host interactions during HIV-1 viral life cycle. J. Neuroimmune Pharmacol. 2011, 6(2):216-229.
60. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004, 78(11):6073-6076.